foxo4-dri senolytic peptide foxo4-dri FOX04-DRI 10mg FOXO4-DRI - Wikipedia

Kenneth Hoober: Acknowledgments This work was supported by Susavion Biosciences

ADCs show growing momentum Antibodydrug conjugates (ADCs) harness the targeting precision of antibodies plus the cytotoxic force of potent small molecules

Drug Des Devel Ther, 2015

10.1002/hep.26379 90 PatijnG

Based on the phase 2 and phase 3 trial protocols: Weeks 1-4: 1 mg once weekly Weeks 5-8: 2 mg once weekly Weeks 9-12: 4 mg once weekly Weeks 13-16: 8 mg once weekly Weeks 17 onward: 12 mg once weekly (maximum dose) The starting dose of retatrutide is deliberately low because the triple-agonist mechanism produces more intense initial side effects than single-pathway compounds